
Please try another search
The cannabis sector has been seen as less susceptible to a COVID-19 related economic slowdown as its consumers either need marijuana medically or are highly reluctant to stop using it recreationally. While some of the bigger players, such as Aurora Cannabis (NYSE:ACB), (TSX:NYSE:ACB) and Cronos Group (NASDAQ:CRON), (TSX:CRON) have seen their share price suffer lately, the smaller Canadian cannabis stocks we’ve dug up have experienced the best upward momentum during the past month.
Indiva (OTC:NDVAF) – $0.445
Indiva a Canadian licensed producer, specializing in creating cannabis derivative products, such as capsules, oils, and edibles, as well as premium pre-rolls and flower, distributing products in seven provinces. The Company also provides production, manufacturing and refinement services to peer partners such as TerrAscend (OTC:TRSSF), (CSE:TER) and The Supreme Cannabis Company (OTC:SPRWF), (TSX:FIRE). On April 23, 2020, Indiva announced preliminary first-quarter 2020 financial and operating results, saying it expects sales to be in the range of $2.0 million to $2.2 million, up from $0.3 million in Q4, reflecting less than two months of edibles sales during the quarter. The Company added that its Bhang chocolate is the #1 selling edible in Ontario. Indiva received its edibles, extracts and topicals sales licence from Health Canada on January 31, 2020.
Aleafia Health (OTC:ALEAF) – $0.63
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company, offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis. Aleafia Health owns three licensed cannabis production facilities, including Canada’s first large-scale, legal outdoor cultivation facility. The Company produces a diverse portfolio of derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents. The Company also maintains a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its education platform FoliEdge Academy. On May 7, 2020, Aleafia Health announced that its indirect subsidiary, Emblem Germany GmbH, has formally submitted its application to German regulators for EU Good Manufacturing Practices certification, which, if successful, would allow for cannabis production and export to the EU market.
48North Cannabis (OTC:NCNNF) – $0.195
48North Cannabis is a vertically integrated cannabis company focused on the health and wellness market through cultivation and extraction, as well as the creation of innovative, authentic brands for next-generation cannabis products. 48North is developing formulations and manufacturing capabilities for its own proprietary products, as well as positioning itself to contract manufacture similar products for third parties. 48North operates Good:Farm, a 100-acre organic cannabis farm, which produces organically-grown, sun-grown cannabis. In addition, 48North operates two indoor-licensed cannabis production sites in Ontario. The Company’s portfolio of brands includes Latitude, a women’s cannabis platform; Avitas, a single-strain vaporizer cartridge; Quill, a leader in the manufacturing of beautifully designed, lifestyle-focused and sleek vape products and; Sackville & Co, a leading U.S.-based cannabis brand focused on design-forward cannabis accessories and CBD products. On April 22, 2020, 48North Cannabis announced that it has shipped the first order of its dried flower brand, Fleur du Jour, to the Société québécoise du cannabis for retail sale.
Many analysts say Tesla is overvalued But Elon Musk has promised star figures for this year Is it time to sell the stock or ride its upward momentum? Tesla (NASDAQ:TSLA) has...
UiPath stock has undergone an impressive rally But is it based on sound fundamentals or just pure speculation? Let's dig deeper into the company's financials and find out Thanks to...
In several recent posts, we discussed our concern over the narrow breadth of the rally in 2023. To wit: “The A.I. chase is making for a very narrow market. As Bob Farrell once...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.